Submitted:
20 April 2020
Posted:
22 April 2020
Read the latest preprint version here
Preprints on COVID-19 and SARS-CoV-2
Abstract
Convalescent blood product therapy has been introduced since early 1900s to treat emerging infectious disease based on the evidence that polyclonal neutralizing antibodies can reduce duration of viremia. Recent large outbreaks of viral diseases for whom effective antivirals or vaccines are still lacking has revamped the interest in convalescent plasma as life-saving treatments. This review summarizes historical settings of application, and surveys current technologies for collection, manufacturing, pathogen inactivation, and banking, with a focus on COVID-19.
Keywords:
convalescent plasma
; serology
; pathogen reduction technologies
; pathogen inactivation
; COVID-19
; SARS-CoV2
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
